Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%

Nurix Therapeutics, Inc.

2024-FY EPS reported -$2.88 revenue$54,549,000

Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.
Cash and marketable securities $609.6M as of Nov 30, 2024, up from $295.3M a year earlier.
NX-5948 achieved 75.5% objective response rate in r/r CLL/SLL; received FDA Fast Track and EMA PRIME designations.
Appointed John Northcott as Chief Commercial Officer in January 2025.
Plans to commence registration trials for NX-5948 in CLL and explore autoimmune indications in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.